Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

Validating survivin as a cancer therapeutic target

Validating survivin as a cancer therapeutic target In mammalian cells, apoptosis is modulated by two protein families — the BCL2 and inhibitor of apoptosis (IAP) families. Survivin is a unique member of the IAP family. It is associated with several subcellular compartments and its expression is regulated by many signalling pathways. The survivin pathway interfaces with both the cell-death machinery and mechanisms of cell-cycle progression and microtubule stability. Survivin expression is undetectable in most normal adult tissues, but is overexpressed in virtually every human tumour that has been studied. Several mechanisms have been proposed to account for this overexpression, one of which is loss of wild-type p53. Is survivin a rational target for cancer therapy? Using molecular antagonists of survivin is one approach for enhancing cell death — specifically of tumours — and could be used in combination with conventional chemotherapy- or radiation-based treatments. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Nature Reviews Cancer Springer Journals

Validating survivin as a cancer therapeutic target

Nature Reviews Cancer , Volume 3 (1) – Jan 1, 2003

Loading next page...
 
/lp/springer-journals/validating-survivin-as-a-cancer-therapeutic-target-QSb8HUXc5I

References (132)

Publisher
Springer Journals
Copyright
Copyright © 2003 by Nature Publishing Group
Subject
Biomedicine; Biomedicine, general; Cancer Research
ISSN
1474-175X
eISSN
1474-1768
DOI
10.1038/nrc968
Publisher site
See Article on Publisher Site

Abstract

In mammalian cells, apoptosis is modulated by two protein families — the BCL2 and inhibitor of apoptosis (IAP) families. Survivin is a unique member of the IAP family. It is associated with several subcellular compartments and its expression is regulated by many signalling pathways. The survivin pathway interfaces with both the cell-death machinery and mechanisms of cell-cycle progression and microtubule stability. Survivin expression is undetectable in most normal adult tissues, but is overexpressed in virtually every human tumour that has been studied. Several mechanisms have been proposed to account for this overexpression, one of which is loss of wild-type p53. Is survivin a rational target for cancer therapy? Using molecular antagonists of survivin is one approach for enhancing cell death — specifically of tumours — and could be used in combination with conventional chemotherapy- or radiation-based treatments.

Journal

Nature Reviews CancerSpringer Journals

Published: Jan 1, 2003

There are no references for this article.